Vyvanse (lisdexamfetamine dimesylate)
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 82 (Table of Contents)
Published: 7 Apr-2007
DOI: 10.3833/pdr.v2007.i82.356 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
Vyvanse™ (lisdexamfetamine dimesylate, NRP104) has been developed by New River Pharmaceuticals using its Carrierwave™ technology, which attaches an API to an adjuvant to create a pharmacologically inactive molecule...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS